![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Howlett H.C.S.
Publisher: Adis International
ISSN: 0114-5916
Source: Drug Safety, Vol.20, Iss.6, 1999-06, pp. : 489-503
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus
Drug Safety, Vol. 33, Iss. 2, 2010-02 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Metformin may reduce the risk of cancer in patients with type 2 diabetes mellitus
Inpharma, Vol. 1, Iss. 1491, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Sitagliptin/Metformin Fixed-Dose Combination: In Patients with Type 2 Diabetes Mellitus
Drugs, Vol. 71, Iss. 3, 2011-02 ,pp. :